EU drug regulator allows Novo Nordisk to include heart condition in Ozempic label

Novo Nordisk announced the European Medicines Agency (EMA) will approve a label expansion for its diabetes drug Ozempic to include peripheral artery disease (PAD), based on positive late-stage trial data demonstrating improved walking distance. This significant regulatory approval, expected to be implemented by the European Commission within two months, broadens Ozempic's therapeutic applications and market potential beyond its existing diabetes and kidney disease indications. Novo Nordisk has also filed for a similar label expansion in the U.S., with a decision anticipated in Q4 2025.

Analysis

Novo Nordisk has achieved a significant regulatory milestone with a positive opinion from the European Medicines Agency (EMA) to expand the label for its drug Ozempic to include peripheral artery disease (PAD). This approval is supported by late-stage trial data demonstrating that Ozempic's active ingredient, semaglutide, improves maximum walking distance in patients with type 2 diabetes and symptomatic PAD. The formal label update by the European Commission is expected within approximately two months, providing a near-term catalyst. This follows a previous successful label expansion for kidney disease risk reduction, underscoring the company's strategy of broadening Ozempic's therapeutic applications. Furthermore, Novo Nordisk has a parallel application for this indication under review in the United States, with a decision anticipated in the fourth quarter of 2025, signaling a potential future growth driver in a key market.

Key Decisions for Investors

• This successful EU label expansion for Ozempic strengthens Novo Nordisk's market position and revenue outlook, supporting a bullish thesis on the stock.
• Investors should monitor the U.S. regulatory process, as the FDA decision in Q4 2025 for the same indication represents a more substantial long-term catalyst.
• Consider the commercial execution risk; the financial impact will depend on the rate of physician adoption and patient uptake for this new peripheral artery disease indication following the official label change.